8-KMaterial AgreementsFinancial EventsExhibits & Filings

AbbVie Inc. 8-K Report, Material Agreement (Sep 26, 2019)

Filed September 26, 2019For Securities:ABBV

Summary

AbbVie Inc. (ABBV) has filed an 8-K report detailing the completion of a significant debt financing transaction on September 26, 2019. The company successfully sold €1.4 billion in senior notes, split between €750 million of 0.750% notes due 2027 and €650 million of 1.250% notes due 2031. This issuance was conducted under a previously filed shelf registration statement and prospectus supplement. The primary purpose of this debt issuance is to redeem, satisfy, and discharge AbbVie's outstanding €1.4 billion of 0.375% senior notes due 2019. Any remaining proceeds, after accounting for any premium and accrued interest on the redeemed notes, will be used for general corporate purposes. This move indicates AbbVie's strategic management of its debt obligations and its approach to optimizing its capital structure.

Key Highlights

  • 1AbbVie completed the sale of €1.4 billion in senior notes on September 26, 2019.
  • 2The issuance consists of two tranches: €750 million of 0.750% senior notes due 2027 and €650 million of 1.250% senior notes due 2031.
  • 3The net proceeds are intended to redeem AbbVie's €1.4 billion of 0.375% senior notes due 2019.
  • 4This transaction is aimed at refinancing existing debt and potentially freeing up cash for general corporate purposes.
  • 5The notes are unsecured, unsubordinated obligations of AbbVie, ranking equally with other unsecured debt.
  • 6The transaction was executed under a shelf registration statement and prospectus supplement filed earlier with the SEC.

Frequently Asked Questions

The primary purpose of issuing the new senior notes was to redeem, satisfy, and discharge AbbVie's outstanding €1.4 billion of 0.375% senior notes due in 2019. Any remaining proceeds will be used for general corporate purposes.

AbbVie issued €1.4 billion in aggregate principal amount of senior notes. This includes €750 million of 0.750% senior notes due 2027 and €650 million of 1.250% senior notes due 2031. These notes are unsecured and unsubordinated obligations.

This issuance allows AbbVie to refinance its maturing 2019 senior notes with new debt. It demonstrates proactive debt management. The company is essentially replacing a maturing debt obligation with new long-term financing, which could impact its interest expense and cash flow depending on the spread between the old and new rates, and the utilization of any remaining proceeds.

No, the new senior notes are unsecured obligations of AbbVie. They rank equally with all of AbbVie's existing and future unsecured, unsubordinated indebtedness.